Replimune Seeks Shareholder Nod to Double Authorized Shares to 300M as Cash Dwindles

summarizeSummary

Replimune's preliminary proxy seeks approval to double authorized shares to 300M, providing headroom for future capital raises as its cash runway extends only into early 2027. Two directors will not stand for reelection, and performance-based equity awards have been extended to align with the delayed FDA review of its lead drug candidate.

check_boxKey Events · Corporate Governance and Compliance · REPL

• Authorized Share Increase Proposed

  Proposal 3 seeks to double authorized common shares from 150M to 300M. As of March 31, 2026, only 30.3M shares remained available for future issuance, and the company faces a going concern with cash runway into Q1 2027.

• Two Directors Not Standing for Reelection

  Class II directors Paolo Pucci and Veleka R. Peeples-Dyer will not be nominated for reelection at the annual meeting, creating two vacancies on the board. The board will evaluate committee composition following the departures.

• PSU Performance Period Extended

  The compensation committee extended the performance period for executive PSUs tied to FDA approval of RP1 to December 24, 2026, reflecting the delayed regulatory timeline after the FDA accepted the BLA resubmission on June 2, 2026.

• Annual Meeting Set for September 15, 2026

  Shareholders of record as of July 21, 2026 will vote on the auditor ratification, say-on-pay, and the authorized share increase. The meeting will be held virtually.

auto_awesomeAnalysis · REPL · Life Sciences

At its September 15 annual meeting, Replimune will ask shareholders to approve a doubling of authorized common shares from 150 million to 300 million. With only 30.3 million shares available for future issuance as of March 31, 2026, and a going concern warning that cash runs out in Q1 2027, the company needs the flexibility to raise capital — likely through dilutive equity offerings. The proxy also reveals two directors are stepping down, creating vacancies on a board that will shrink to eight members. Separately, the compensation committee extended the performance period for executive PSUs tied to FDA approval of RP1 to December 24, 2026, reflecting the delayed regulatory timeline.